Amyloid alone does not confirm that Alzheimer's disease is progressing rapidly. Here's what people need to know about the ...

Weill Cornell Medicine researchers have received a five-year $6.2 million grant from the National Institute on Aging, part of the National Institutes of Health, to build a portable, high-resolution ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Offering a simpler alternative to PET scans and CSF analysis, blood-based biomarker tests could improve accessibility of ...

PET scans can help detect Alzheimer’s at an early stage, guide treatment decisions, and support the development of new therapies by tracking disease progression. One of the major hospitals in ...

GlobalData reports that at least five pipeline devices are now in the regulatory approval process across the US and Europe, ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia Limited (Lilly) have signed a ...

Researchers from the International Working Group recommend categorizing biomarker-positive, cognitively normal individuals as ...

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi Arabia signed an MoU today to improve Alzheimer's patient care.

Weill Cornell Medicine researchers have received a five-year, $6.2 million grant from the National Institute on Aging, part of the National Institutes ...

The memorandum of understanding (MOU) between the companies aims to advance the development of imaging agents used in PET scans.